Article and Video CATEGORIES
ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC by Dr. David Gerber
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
[powerpress]
ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC Audio Podcast
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Can SCLC also be treated with targeted therapy?
Hi amitchouhan,
Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...
I was searching for this, Thank you so much for the info.